Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000594151 | SCV000708184 | uncertain significance | not provided | 2017-05-03 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000594151 | SCV002063136 | uncertain significance | not provided | 2022-10-01 | criteria provided, single submitter | clinical testing | SLC10A1: PM2, PM5, PP4 |
Mayo Clinic Laboratories, |
RCV000594151 | SCV004226674 | likely pathogenic | not provided | 2022-06-22 | criteria provided, single submitter | clinical testing | PM2, PM5, PS3 |
Prevention |
RCV004748847 | SCV005349339 | uncertain significance | SLC10A1-related disorder | 2024-08-20 | no assertion criteria provided | clinical testing | The SLC10A1 c.754C>A variant is predicted to result in the amino acid substitution p.Arg252Ser. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0089% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |